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ABSTRACT
Objectives: Concerns have been raised about a
possible link between bisphosphonate use, and in
particular alendronate, and upper gastrointestinal (UGI)
cancer. A number of epidemiological studies have been
published with conflicting results. We conducted a
systematic review and meta-analysis of observational
studies, to determine the risk of esophageal and
gastric cancer in users of bisphosphonates compared
with non-users.
Design: We searched PubMed, MEDLINE, EMBASE,
Web of Knowledge and Cochrane Database of
Systematic Reviews for studies investigating
bisphosphonates and esophageal or gastric cancer. We
calculated pooled ORs and 95% CIs for the risk of
esophageal or gastric cancer in bisphosphonate users
compared with non-users. We performed a sensitivity
analysis of alendronate as this was the most common
single drug studied and is also the most widely used
in clinical practice.
Results: 11 studies (from 10 papers) examining
bisphosphonate exposure and UGI cancer (gastric and
esophageal), met our inclusion criteria. All studies
were retrospective, 6/11 (55%) case–control and 5/11
(45%) cohort, and carried out using data from 5
longitudinal clinical databases. Combining 5 studies (1
from each database), we found no increased risk, OR
1.11 (95% CI 0.97 to 1.27) of esophageal cancer in
bisphosphonate users compared with non-users and
no increased risk of gastric cancer in bisphosphonate
users, OR 0.96 (95% CI 0.82 to 1.12).
Conclusion: This is the fourth and most detailed
meta-analysis on this topic. We have not identified any
compelling evidence for a significantly raised risk of
esophageal cancer or gastric cancer in male and
female patients prescribed bisphosphonates.
INTRODUCTION
There has been a major rise in the prescrib-
ing of bisphosphonates in general and alen-
dronate in particular. In 1992, 0.2% of
women over 40 included in the UK General
Practice Research Database (GPRD) were
prescribed a bisphosphonate, but by 2005
this had risen to 4·1% according to Watson
et al1 and to between 4.6% and 4.8% in the
period from 1997 to 2011 in Vinogradova
et al’s2 study. At the same time, there has
been a parallel reduction in hormone
replacement therapy prescribing from 8·2%
in 1991 to 7·0% in 2005, with a 50% fall
since 2002, largely driven by concerns over
an excess risk of breast cancer and cardiovas-
cular events.1
Bisphosphonates and particularly alendro-
nate are well known to cause both dyspepsia
and inﬂammatory changes such as erosive
esophagitis, delayed healing and mucosal
abnormalities.3 Multinucleated giant cells
have been detected in esophageal inﬂamma-
tory exudates. Whether these can undergo
malignant transformation is not known, but
concerns have been raised as to a possible
link between bisphosphonate use and UGI
(upper gastrointestinal) cancer.4 5
Strengths and limitations of this study
▪ Thirteen retrospective studies testing the associ-
ation between bisphosphonates and upper
gastrointestinal cancer have now been published
with conflicting results and three meta-analyses
also with differing results.
▪ This is the fourth and most comprehensive
meta-analysis, bringing the overall number of
negative or no increased risk meta-analyses to
three and one positive meta-analysis.
▪ A particular problem was the use of overlapping
cohorts in the same database, which reduced the
numbers of studies we were able to combine
because of the risk of double counting.
▪ This study provides additional reassurance to
prescribers and users of bisphosphonates but
ultimately long term, sufficiently large, prospect-
ive studies will be needed to definitively answer
this question.
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Since Wysowski’s4 report to the US Federal Drug
Administration in 2009, noting that since the initial mar-
keting of alendronate in 1995, the Federal Drug
Administration had received 23 case reports of patients
who developed esophageal tumours after taking the
drug, there have been a number of observational
studies, most in large national databases, looking at a
possible association between bisphosphonate use and
UGI cancer, but the results have been conﬂicting. There
have also been three published meta-analyses to date,
the latest published in 2013. These too have conﬂicting
results with one analysis by Andrici et al,6 showing a sig-
niﬁcant positive association between bisphosphonates
and esophageal cancer, the second by Sun et al,7
showing no increased risk, and the third by Oh et al,8
showing no signiﬁcant association but indicated a pos-
sible increased risk in long-term users of bisphospho-
nates. In view of the continuing uncertainty, a further
review including later, larger studies, Wright et al9 and
Vinogradova et al,2 was indicated. We are mindful of the
recent BMJ paper by Siontis et al10 criticising the increas-
ing trend of duplicate meta analyses. We considered this
one justiﬁed because of: (1) the continuing increased
prescribing of these drugs,11 (2) the seriousness of the
potential adverse effect, and (3) the current uncertainty
of the precise effectiveness of these drugs in long-term
fracture prevention.12
METHODS
We carried out a systematic review and meta-analysis to
test the association between bisphosphonate prescribing
and esophageal and gastric cancer. We identiﬁed all
cohort and case–control and any prospective studies
published to that date, assessed the quality of those
studies according to preset criteria as described below,
compared the risk ratios obtained and where possible
combined the results into a meta-analysis to yield a reli-
able estimate of the risk. The reporting adequacy of
each cohort, case–control and cross-sectional study
was assessed using the ‘Strengthening the Reporting of
Observational studies in Epidemiology’ (STROBE) state-
ment. For each study, introduction, methodology, results
and discussion sections were reviewed and areas of bias,
overall interpretation and generalisability of the publica-
tion were reported. We followed the MOOSE guidelines
for systematic reviews and meta-analyses. For review of
study quality including bias, individual studies were
reviewed using GRADE guidelines for eligibility criteria,
measurement of exposure and outcome, confounders
and follow-up. The search and study selection was
carried out independently by EW and MM and consen-
sus reached by discussion.
Search strategy
We searched the following databases—EMBASE,
PubMed, MEDLINE, Web of Knowledge (WOK) and
Cochrane Database of Systematic Reviews (CDSR) from
inception to 30 March 2015 using the terms ‘esophageal
cancer’, ‘oesophageal cancer’, ‘gastric cancer’, ‘bispho-
sphonates’ and ‘alendronate’. The search strings are
detailed in the online supplementary material.
Language was restricted to English. The abstracts were
scanned for retrospective and prospective studies involv-
ing adverse effects of bisphosphonates. The reference
lists of relevant articles were also hand searched for
further studies.
Study selection
Studies were included if they met the following criteria:
(1) the study used a case–control or cohort design; (2)
the study examined bisphosphonates and the risk of
esophageal and/or gastric cancer; (3) the risk estimate
was reported as an OR, HR or relative risk; (4) the 95%
CI for the risk estimate was included. Where there were
multiple studies per database we selected a ‘best in class’
study based on a number of factors including study
quality, number of cases, eligibility criteria, measurement
of exposure and outcome, confounders and follow-up.
Data extraction
The data from the studies was extracted onto an elec-
tronic standardised form that included author, year of
publication, country, source of participants, study type,
drugs studied and dosage, age and gender of partici-
pants, study population including numbers of exposed
and unexposed cases, exclusion criteria, mean years
exposure and follow-up, cancer outcome studied, crude
and adjusted risk estimates, 95% CI, variables adjusted
for, funding source and additional comments.
Adjusted risk estimates were used in preference to
unadjusted estimates, if available. Multiple risk estimates
were listed separately for each study and identiﬁed separ-
ately for differing outcomes and drugs, for example, all
bisphosphonates/alendronate and category of cancer:
(1) esophageal, (2) gastric or (3) UGI cancer.
Statistical analysis
The analyses were as follows: (1) esophageal cancer and
all bisphosphonates; (2) gastric cancer and all bispho-
sphonates; (3) esophageal cancer and alendronate; (4)
gastric cancer and alendronate; (5) cohort studies—UGI
cancer and all bisphosphonates; and (6) case–control
studies—UGI cancer and all bisphosphonates.
For each analysis, we selected one study from each
database, by consensus, using the following criteria:
quality of study, number of exposed cases, adjustment
for important confounders and precision of risk esti-
mate. We calculated a pooled OR for the effect of
bisphosphonates or alendronate, weighted by study pre-
cision. We tested for between-study heterogeneity, where
the true underlying effect varies between trials, using
Cochrane’s Q. This was quantiﬁed using the I2 statistic,
giving the proportion of overall variation this accounts
for. Where the p <0.1 or I2>50%, we used a
random-effects model to calculate the pooled estimate
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accounting for heterogeneity. Otherwise, we used a
ﬁxed-effects model that assumes each study measures
the same underlying effect. We carried out sensitivity
analyses to examine the effect of substituting alternative
studies and/or risk estimates from the same database in
the groups. All statistical analyses were carried out using
Stata V.13.0 (Stata Corp, College Station, Texas, USA). A
funnel plot (see online supplementary ﬁgure S1) was
used to assess publication bias.
RESULTS
In total, 412 articles were found to be potentially rele-
vant from the electronic database search (ﬁgure 1).
Seventy-two abstracts were screened, the remainder
rejected as they were review articles, opinion pieces or
otherwise not original research. Thirteen studies were
initially identiﬁed as testing the association between
bisphosphonate prescribing and esophageal and/or
gastric cancer. One study by Ho et al13 was rejected as it
did not provide any information on the precision of the
study, and a further two by Solomon et al14 and
Abrahamsen et al15 as they were letters and not peer-
reviewed studies, leaving ﬁve retrospective cohort studies
and six case–control studies (from ﬁve papers identiﬁed
from the literature search). The main characteristics of
the individual studies are listed in table 1. One study by
Vinogradova et al2 actually involved the use of two differ-
ent UK databases (Clinical Practice Research Data Link
Database (CPRD) and Q-Research (QRes)), testing the
same association, so has been treated as two studies for
the analyses and listed as such in table 1.
The studies came from ﬁve longitudinal clinical data-
bases in four different countries—the USA, the UK,
Denmark and Taiwan. In the cohort studies, the number
of patients exposed to bisphosphonates varied from
30 606 (all UGI cancer,16) to 55 090 (alendronate,
Vestergaard17). In the case–control studies, the number
of cases of esophageal cancer varied from 11618 to
5364.2
Studies were selected and grouped for the analyses
according to the criteria mentioned in the Methods
section. A meta-analysis was performed for each of the
groups and sensitivity analyses were carried out to
examine the effect of substituting alternative studies
and/or risk estimates in the groups. The ﬁndings are
summarised in table 2 and described below under separ-
ate headings for each group.
DNR—Danish National Registries, CPRD (formerly
GPRD), QRes database, NHICD—National Health
Insurance Claims Database, VAD—Veterans Affairs
Database.
Esophageal cancer and all bisphosphonates
We found no signiﬁcant association between use of
bisphosphonates and esophageal cancer, OR 1.11 (0.97
to 1.27), in the studies selected (ﬁgure 2). We per-
formed a number of sensitivity analyses examining
different combinations of CPRD studies used; the results
essentially were very similar, and all non-signiﬁcant. An
initial sensitivity analysis substituting Wright2 as an alter-
native CPRD study (see online supplementary ﬁgure
S2.1) found that although the risk ratio increased
slightly, the results remained non-signiﬁcant with an
overlapping CI, OR 1.29 (0.97 to 1.72). We then per-
formed further sensitivity analyses substituting Green
et al20 as an alternative CPRD study and Chen et al21 as
the alternative Taiwanese database study (see online sup-
plementary ﬁgure S2.2) and found a non-signiﬁcant
pooled risk estimate, OR 1.11 (0.95 to 1.29). In a third
sensitivity analysis further substituting Cardwell et al19 as
the CPRD study and Lee et al23 as the Taiwanese study
(see online supplementary ﬁgure S2.3), there was no
apparent increased risk, OR 1.03 (0.88 to 1.22).
Gastric cancer and all bisphosphonates
We found no signiﬁcant association between use of
bisphosphonates and gastric cancer (ﬁgure 3), OR 0.96
(95% CI 0.82 to 1.12).
Esophageal cancer and alendronate
We found no increased risk, OR 0.98 (0.87 to 1.11), of
esophageal cancer in alendronate users (ﬁgure 4). We
performed three sensitivity analyses—the ﬁrst substitut-
ing Wright et al9 as the alternative CPRD study and Chen
et al21 as the alternative Taiwanese study (see online sup-
plementary ﬁgure S4.1). We found a similar non-
signiﬁcant OR 0.97 (0.70 to 1.34). We then substituted
Cardwell et al19 as the CPRD study (see online supple-
mentary ﬁgure S4.2). This resulted in a non-signiﬁcant
risk ratio, OR 0.85 (0.71 to 1.02). The third, substituting
Lee et al23 as the alternative Taiwanese study (see online
supplementary ﬁgure S4.3) also gave a non-signiﬁcant
risk ratio, OR 0.86 (0.72 to 1.04). Overall, we therefore
found no signiﬁcant association between alendronate
and esophageal cancer.
Gastric cancer and alendronate
We found no increased risk of gastric cancer with alen-
dronate (see online supplementary ﬁgure S5), OR 0.99
(95% CI 0.71 to 1.38).
Cohort studies—UGI cancer and all bisphosphonates
Combining all the cohort studies did not show any sig-
niﬁcantly increased risk of UGI cancer with bisphospho-
nates (see online supplementary ﬁgure S6), OR 1.32
(95% CI 0.81 to 2.13).
Case–control studies—UGI cancer and all
bisphosphonates
Combining all the case–control studies also did not
show any signiﬁcantly increased risk of UGI cancer with
bisphosphonates (see online supplementary ﬁgure S7),
OR 1.06 (95% CI 0.93 to 1.22).
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DISCUSSION
Since the original case reports commented on by
Wysowski4 in the New England Journal of Medicine, bispho-
sphonates and the risk of esophageal cancer has been a
controversial but important topic, as although esophageal
cancer is fortunately rare with UK incidence of 9.7/
10 000,24 the outcomes are poor and even a small increase
in risk would have a signiﬁcant effect on morbidity and
mortality. Other potential harms of bisphosphonates have
been raised including increased rates of low-impact
femoral fractures, atrial ﬁbrillation and osteonecrosis of
the jaw.25 At the same time, the effectiveness of bispho-
sphonates in fracture prevention is being questioned.12
We have systematically searched the literature and
reviewed all the existing studies testing the association
between bisphosphonates and esophageal or gastric
cancer and performed a meta-analysis. The results do
not support an association between bisphosphonates
overall and esophageal or gastric cancer, nor for the sen-
sitivity analyses an increased risk of esophageal cancer in
patients prescribed alendronate, a concern raised in the
case reports submitted to the US Federal Drug
Administration in 2009,4 although it is possible that
studies that examined bisphosphonates as a class in asso-
ciation with UGI cancer risk may have diluted the effect
of risks associated with alendronate. Furthermore, sensi-
tivity analyses examining (1) effects of alendronate and
(2) substituting different studies from each database for
primary and secondary analyses showed largely similar
(non-signiﬁcant) results.
Comparisons with other studies
Exposure varies with some studies looking at all bispho-
sphonates combined whereas others look at alendronate
alone and some, for example, Vestergaard,17 quote indi-
vidual risk ratios for bisphosphonates (etidronate, rise-
dronate). Length of exposure to bisphosphonates also
varies across the studies.
Outcomes of the studies likewise vary—most examined
esophageal cancer, some gastric cancer, some16 19 com-
bining into all UGI cancer and others looking at other
gastrointestinal tract cancers20 and non-gastrointestinal
cancers.17 22 23 Previous studies have established good
validity of READ UGI cancer codes.26 However, an add-
itional difﬁculty is misclassiﬁcation arising from the lack
of precise coding of the histological subtype of esopha-
geal cancer available in primary care records, which
were not available for this study. Esophageal adenocar-
cinoma is thought to be increasing, as a proportion of
all esophageal tumours compared with squamous cell,
potentially related to the increasing prevalence of
gastro-esophageal reﬂux disease (GORD). It may be dif-
ﬁcult to differentiate between esophageal adenocarcin-
oma and gastric carcinoma at the gastro-oesophageal
junction. It would, therefore, be helpful in future studies
to be able to link primary care database information to
cancer registry data to look at the association between
bisphosphonates and particular subtypes of esophageal
and gastric cancer.
Thirteen retrospective studies have now been pub-
lished with conﬂicting results and three meta-analyses
Figure 1 Study selection flow
diagram (CDSR, Cochrane
Database of Systematic Reviews;
WOK, Web of Knowledge).
4 Wright E, et al. BMJ Open 2015;5:e007133. doi:10.1136/bmjopen-2014-007133
Open Access
group.bmj.com on March 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 1 Characteristics of the studies testing the association between bisphosphonate prescribing and esophageal and gastric cancer or UGI cancer
Author,
country,
year of
publication
Gender
(mean
age,
years)
Study population
(exposed/cases)
Study population
(controls)
nclusion/exclusion
criteria
Follow-up (mean
years)
Outcome
studied—
cancer type/drug
(number of
exposed cases if
quoted)
Risk ratio (p
Value), 95% CI
Adjusted
variables Comments
Vestergaard,
Denmark,
201117
M+F
(70.5)
Cohort of 103 562
bisphosphonate
users, subset of
53 935 (alendronate
users) from Danish
National Registries
including the
National
Pharmacological
Database
310 683 age-matched
and sex-matched
controls from the
general
population,161 207
alendronate-matched
controls
Patients prescribed any
bisphosphonate
between 1/1/96 and 31/
12/06/ Prior GI
malignancy
>5 Esophageal/
alendronate (14)
Gastric/alendronate
(10)
2.1, 1.01 to 4.35
1.16, 0.54 to 2.53
Age, gender,
alcohol, inhaled
bronchodilator or
steroid therapy
(smoking proxy),
antacids, NSAID,
employment,
marital status,
income, prior
gastric surgery
Funded By AP Moller
Foundation, Servier and
Dandy
Abrahamsen
et al,
Denmark,
201216
F (79) Cohort of 30 606
females from
Danish National
Registries between
1995 and 2005,
prescribed
alendronate
122 424 patients,
matched 4:1 on gender
and year of birth
Women aged 50±/Prior
hospital diagnosis of
any cancer
3.5 UGI/alendronate (44)
Esophageal/
alendronate (19)
Gastric/alendronate
(22)
0.63, 0.45 to 0.87
0.71, 0.43 to 1.19
0.61, 0.39 to 0.67
age, gender, PPI
use, upper
endoscopy,
co-medications,
Charlton
comorbidity index
Researchers have
grants from Merck
(makers of alendronate)
and multiple other drug
companies
Cardwell
et al, UK,
201019
M+F
(70)
Cohort of 41 826
patients on
bisphosphonates
from the UK
General Practice
Research Database
41 826 age, sex and
GP practice-matched
controls
Patients treated with
oral bisphosphonates
between January 1996
and December 2006/
patients with less than
6 months follow-up
4.5
bisphosphonates/
4.4 controls
UGI/bisphosphonate
(116)
Esophageal/
bisphosphonate (79)
UGI/alendronate (55)
Esophageal/
alendronate (33)
096, 0.74 to 1.25
1.07, 0.77 to 1.49
0.79, 0.55 to 1.15
0.77, 0.48 to 1.23
Age, gender,
smoking, alcohol,
BMI,GP practice
Funded by CPRD/MRC
licence
Green et al,
UK, 201020
M+F
(72)
2954 cases of
esophageal cancer,
2018 cases of
gastric cancer,
10 641 cases of
colorectal cancer
from the UK
General Practice
Research Database
14 770 controls
matched 5:1 per case
Men and women aged
40+diagnosed between
1995 and 2005 with at
least 12 months
follow-up before
diagnosis/patients
treated with
bisphosphonates
licensed for Paget’s
disease or bone
metastases
7.5 Esophageal/
bisphosphonate (90)
Esophageal
(<10 prescriptions)
Esophageal
(>10 prescriptions)
Gastric (49)
Colorectal (276)
13, 1.02 to 1.66
0.93, 0.66 to 1.31
1.93, 1.37 to 2.70
0.87, 0.64 to 1.19
0.87, 0.77 to 1.00
Smoking, gender,
age, alcohol, BMI
Funded by CPRD/MRC
licence
Wright et al,
UK, 20129
M+F
(64.7)
5226 cases of
esophageal cancer,
3410 cases of
gastric cancer from
the UK General
Practice Research
Database
20 904 and 13 640
controls matched 4:1
by age and sex
All men and women
registered with practices
with up to standard data
in the CPRD from 1995
to 2007
6.1 UGI/bisphosphonate
(342)
Esophageal/
bisphosphonate
(225)
Gastric/
bisphosphonate (93)
F Esophageal/
alendronate (95) F
13, 1.21 to 1.39
1.43, 1.18 to 1.72
1.06, 0.83 to 1.35
1.42, 1.1 to 1.83
Smoking
smoking
Gender difference
identified. Funded by
CPRD/MRC licence
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Table 1 Continued
Author,
country,
year of
publication
Gender
(mean
age,
years)
Study population
(exposed/cases)
Study population
(controls)
nclusion/exclusion
criteria
Follow-up (mean
years)
Outcome
studied—
cancer type/drug
(number of
exposed cases if
quoted)
Risk ratio (p
Value), 95% CI
Adjusted
variables Comments
Vinogradova
et al, UK,
20132
M+F
(>50)
5132 cases of
esophageal cancer
from CPRD 3157
cases of gastric
cancer
23 110 controls 14 686
controls
Patients aged above 50
with at least 2 years of
data before index date/
patients with
prescriptions of
bisphosphonates
licensed for
malignancies, patients
with Paget’s disease
Stratified<6,
7–36, 37–72,
≥73 months
Esophageal/
bisphosphonate
(262)
Esophageal/
alendronate(167)
Gastric/
bisphosphonate
(139)
Gastric/alendronate
(100)
1.18 (0.09), 0.97
to 1.43
1.03 (0.8), 0.83 to
1.13
0.79 (0.06), 0.62
to 1.01
0.93 (0.6), 0.71 to
1.22
BMI, smoking,
alcohol, ethnicity,
osteoporosis
history, previous
fracture, steroid
use, H2
antagonists, PPIs,
antacids, NSAIDs,
vitamin D
prescribed more
than 1 year before
Nested case–control
using two large national
databases funded by
University of Nottingham
Vinogradova
et al, UK,
20132
M+F
(>50)
5364 cases of
esophageal cancer
from Q-Research
database3155
cases of gastric
cancer
25 101 controls,
matched 5:1 by age,
sex, practice and
calendar year 14 715
controls
As above Stratified <6,
7–36, 37–72,
≥73 months
Esophageal/
bisphosphonate(252)
Esophageal/
alendronate(163)
Gastric/
bisphosphonate
(141)
Gastric/alendronate
(102)
0.97 (0.7), 0.79 to
1.18
0.91 (0.4), 0.73 to
1.14
1.12 (0.4), 0.87 to
1.44
1.47 (0.008), 1.11
to 1.95
As above As above
Nguyen et al,
USA, 201018
97% M
(69)
116 cases of
incident EAC out of
11 823 patients with
BE from the US
Department of
Veterans Affairs
Database
696 controls matched
6:1 on age (± 5 years)
and BE index date (±
14 days)
Patients aged 18–90
with ICD code for BE
and endoscopy 1 year
before BE index date to
9 months after/Pts with
ICD code for EAC
between 10/96 and
6 months after BE index
date
691 days (SD
386)
Esophageal/
alendronate
092, 0.21 to 4.15 Completed
bisphosphonate
prescriptions were very
uncommon (17% in
cases vs 19% in
controls) Funding—NIH
and Texas Gulf Coast
Digestive Diseases
Center
Chen et al,
Taiwan,
201121
M+F 282 cases of
esophageal cancer
from a cohort of
osteoporosis
treatment initiators
between 2001 and
2008 from National
Health Insurance
Research Database
2811 controls without
cancer matched by
age, sex and cohort
entry year
Cases hospitalised for
esophageal cancer
since entry into cohort
1 Esophageal/
alendronate (88)
0.61 (0.36), 0.21
to 1.75
Age, sex,
comorbidities, PPI
use, cohort entry
Government-funded
research (National
Science Council)
Chiang et al,
Taiwan,
201222
F
(73.5)
Cohort of 6906
women selected
from NHRI cohort
(1 000 000
randomly selected
patients of National
Health Insurance
Claims Database
from 1995 onward)
20 697 women with
osteoporosis, age and
comorbidity matched,
with no record of taking
bisphosphonates
between 1996 and
2009
Women with
osteoporosis over
55taking alendronate
from 1 January 1998 to
31 December 2009/
exposure to oral steroids,
malignancy, vitamin D
deficiency,
hyperparathyroidism,
4.8 All cancers/
alendronate (821)
Esophageal/
alendronate (13)
Gastric/alendronate
(37)
1.05, 0.97 to 1.93
1.5, 0.78 to 2.88
1.04, 0.72 to 1.50
Age, gender,
hypertension,
diabetes, COPD,
dyslipidaemia,
CKD, CAD,
colorectal polyp,
benign breast
disease, obesity,
statin use
NHRI cohort is
representative of general
Taiwanese population.
Not controlled for
smoking or alcohol.
Study supported by
grants from National
Science council and
Continued
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also with differing results. There have been no prospect-
ive studies to date. The numbers in the studies vary from
very large database studies, 16 808 cases of UGI cancer
with 5 controls per case, Vinogradova et al,2 to small
disease-speciﬁc series, 116 cases of esophageal cancer
from a cohort of 11 823 patients with Barrett’s esopha-
gus, Nguyen et al.18 With rare cancers, such as UGI
cancers fortunately are, it is difﬁcult to obtain the requis-
ite numbers of exposed cases in prospective cohort
studies. The Vestergaard17 study, by far the largest with a
cohort of 103 562 bisphosphonate users, still only had
14 esophageal cancer cases exposed to alendronate com-
pared with Wright et al’s9 225 esophageal cancer cases
exposed to bisphosphonates. There was no signiﬁcant
increased risk or difference in risk estimates comparing
cohort versus case–control studies overall.
There is signiﬁcant variation in the confounders that
studies adjusted for. Most studies controlled for age,
gender and smoking (a major risk factor for UGI
cancer), but for reasons that are not clear, none of the
Taiwanese studies control for smoking and this limits
their validity. Only one study by Vinogradova et al2 con-
trols for osteoporosis, the risk factors for which overlap
with those for UGI cancer, and this is clearly a limitation
of other studies. Variation in recording of and accuracy
of confounders in the databases is the likely explanation
for such discrepancies; however, only database studies
using existing information are likely to provide the
numbers of cases needed for analysis of the risk of devel-
oping a rare disease as a result of drug exposure.
Some studies included patients with mean duration of
bisphosphonate use >5 years.2 9 20 Green et al20 showed an
increased risk of esophageal cancer with increasing dur-
ation of bisphosphonate use, OR 1.93 (CI 1.37 to 2.70),
stratiﬁed as >10 prescriptions (which is likely to include
shorter periods of duration of use). Data from Lee et al23
examining association of UGI cancer with bisphosphonate
annual dosage (bisphosphonate burden >1 g) were incon-
clusive with wide CIs due to very small numbers.
Vinogradova et al2 stratiﬁed by duration of use >72 months
and showed increased risk of bisphosphonates with
esophageal cancer (no increased risk with gastric cancer)
in CPRD only, OR 1.63 (1.03 to 2.59); p=0.04 (although
authors state this was above the 0.01 signiﬁcance threshold
applied due to the number of comparisons made). Data
for esophageal cancer risk with alendronate were stratiﬁed
only by ≥1 year duration of usage and showed no signiﬁ-
cant increased risk. Although our previous study had
mean duration of use of 6.1 years, we did not stratify risk
by duration of use.9 Owing to the lack of data (and consist-
ency of long duration exposures), we were unable to
examine this formally in the meta-analysis.
Strengths
There have been three meta analyses to date with con-
ﬂicting results—one showing an effect, Andrici et al,6
and two no effect, Oh et al8 and Sun et al.7 We focused
on extracting data for all bisphosphonates and
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alendronate as these were the two most common cat-
egories studied. Wherever possible, we used the most
adjusted estimate available. Our meta-analysis is the
largest and most complete one to date which, unlike the
others, includes both the latest study using two UK data-
bases (CPRD and QRes) by Vinogradova et al2 and our
Table 2 Combined estimates and sensitivity analyses for each of the groups
Cancer and drug Studies
Combined risk estimate
(95% CI)
Esophageal cancer and all
bisphosphonates—main analysis
Vestergaard-DNR, Vinogradova-CPRD,
Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD
1.11 (0.97 to 1.27)
Sensitivity analysis (1) Vestergaard-DNR, Wright-CPRD, Vinogradova-QRes,
Chiang-NHICD, Nguyen-VAD
1.29 (0.97 to 1.72)
Sensitivity analysis (2) Vestergaard-DNR, Green-CPRD, Vinogradova-QRes,
Chen-NHICD, Nguyen-VAD
1.11 (0.95 to 1.29)
Sensitivity analysis (3) Vestergaard-DNR, Cardwell-CPRD, Vinogradova-QRes,
Lee-NHICD, Nguyen-VAD
1.03 (0.88 to 1.22)
Gastric cancer and all
bisphosphonates
Vestergaard-DNR, Vinogradova-CPRD,
Vinogradova-QRes, Chiang-NHICD
0.96 (0.82 to 1.12)
Esophageal cancer and alendronate—
main analysis
Abrahamsen-DNR, Vinogradova-CPRD,
Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD
0.98 (0.87 to 1.11)
Sensitivity analysis (1) Abrahamsen-DNR, Wright-CPRD, Vinogradova-QRes,
Chen-NHICD, Nguyen-VAD
0.97 (0.70 to 1.34)
Sensitivity analysis (2) Abrahamsen-DNR, Cardwell-CPRD,
Vinogradova-QRes, Chen-NHICD, Nguyen-VAD
0.85 (0.71 to 1.02)
Sensitivity analysis (3) Abrahamsen-DNR, Cardwell-CPRD,
Vinogradova-QRes, Lee-NHICD, Nguyen-VAD
0.86 (0.72 to 1.04)
Gastric cancer and alendronate Abrahamsen-DNR, Chiang-NHICD, Vinogradova-QRes,
Vinogradova-CPRD
0.99 (0.71 to 1.38)
Upper GI cancer and all
bisphosphonates
Cohort studies: Vestergaard-DNR, Cardwell-CPRD,
Chiang-NHICD
1.32 (0.81 to 2.13)
Upper GI cancer and all
bisphosphonates
Case control studies: Vinogradova-CPRD,
Vinogradova-QRes, Nguyen-VAD, Chen-NHICD
1.06 (0.93 to 1.22)
CPRD, Clinical Practice Research Data Link Database; DNR, Danish National Registries; GI, gastrointestinal; NHICD, National Health
Insurance Claims Database; Qres, Q-Research; VAD, Veterans Affairs Database.
Figure 2 Meta-analysis of risk of esophageal cancer with any bisphosphonate. CPRD, Clinical Practice Research Data Link
Database; DNR, Danish National Registries; ES, effect size; NHICD, National Health Insurance Claims Database; Qres,
Q-Research; VAD, Veterans Affairs Database.
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own GPRD study by Wright et al.9 For each of our ana-
lyses, to avoid double counting we selected one study
from each database, by criteria outlined earlier (study
quality, number of cases, precision of the risk estimate,
adjustment for confounders) to select the best in class.
Limitations
A particular problem was the use of overlapping cohorts
in the same database, which reduced the numbers of
studies we were able to combine because of the risk of
double counting. For example, there were four studies
Figure 3 Meta-analysis of gastric cancer with any bisphosphonate. CPRD, Clinical Practice Research Data Link Database;
DNR, Danish National Registries; ES, effect size; NHICD, National Health Insurance Claims Database; QR, Q-Research.
Figure 4 Meta-analysis of risk of esophageal cancer with alendronate. CPRD, Clinical Practice Research Data Link Database;
DNR, Danish National Registries; ES, effect size; NHICD, National Health Insurance Claims Database; Qres, Q-Research; VAD,
Veterans Affairs Database.
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using the UK CPRD, formerly GPRD,2 9 19 20 two studies
using the DNR16 17 and three studies using the Taiwan
NHICD.21–23 This necessarily limited the power of the
analysis. A further problem that limited the number of
studies for meta-analyses including sensitivity analyses,
was the differing outcomes and exposures selected.
CONCLUSIONS AND RECOMMENDATIONS
There have been three meta-analyses to date with
conﬂicting results. We have added two further
studies and followed clear and objective criteria for
selection of the best study from each database for the
analyses.
Our analyses did not ﬁnd a signiﬁcant increased risk
between bisphosphonate exposure and gastric or
esophageal cancer, or alendronate (the majority of
prescribed bisphosphonates) and esophageal cancer.
However, we are aware that lack of evidence for
an association does not prove the absence of an
association.
Bisphosphonates in general and alendronate in par-
ticular are being recommended by current osteoporosis
prevention guidelines to increasing numbers of men
and women in predominantly older age groups.
Alendronate is the most commonly prescribed bispho-
sphonate, and most commonly associated with gastric
irritation and erosive esophagitis which could be a plaus-
ible mechanism for causation (irritation of the gastric
and esophageal mucosa). With a rare disease such as
this, very large prospective cohort studies would be
required with sufﬁciently long follow-up to conﬁrm and
quantify the associated risk; however, none have been
published to date. Despite the inconclusive result of this
latest meta-analysis, it would be sensible to exercise
caution in prescribing bisphosphonates to patients with
pre-existing risk factors for UGI cancer, and to have a
lower threshold for investigating such patients, should
they develop symptoms suggestive of UGI cancer.
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